Tag: DBV Technologies

December 20, 2018

DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age

DBV Technologies (Nasdaq:DBVT) announced that after discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA)...
December 12, 2018

DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018

DBV Technologies (Euronext:DBV;Nasdaq:DBVT), a clinical-stage biopharmaceutical company, announced that an oral abstract evaluating differences in the immune profile of healthy...
October 22, 2018

DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration

DBV Technologies (Euronext: DB – ISIN: FR0010417345;Nasdaq:DBVT) today announced the submission of a Biologics License Application (BLA) to the U.S....
November 8, 2016

DBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic Patients

DBV Technologies, today announced that enrollment for Part B, or Phase II, of the Phase I/II study of Viaskin Milk...
September 20, 2016

DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow’s Milk Protein Allergy

DBV Technologies (NASDAQ:DBVT), announced that the USFDA has granted Fast Track designation for Viaskin Milk, the Company’s investigational treatment for...
March 7, 2016

DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin(R) Peanut Safety and Efficacy

DBV Technologies (NASDAQ:DBVT) announced the presentation of results from CoFAR6, a Consortium of Food Allergy Research (CoFAR) study sponsored by...